Oestrogen receptor α increases p21WAF1/CIP1 gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells

Journal of Endocrinology

Volumn 179, Issue 1, 2003, Pages 41-53

  Margueron, R ^a   Licznar, A ^a   Lazennec, G ^a   Vignon, F ^a   Cavailles V ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PROTEIN P21; TRANSCRIPTION FACTOR SP1; TRICHOSTATIN A;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ACETYLATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TRANSPORT; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; VIRUS INFECTION;

ACETYLATION; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; NEOPLASM PROTEINS; RECEPTORS, ESTROGEN; SP1 TRANSCRIPTION FACTOR; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0142182098     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1790041     Document Type: Article

References (44)

1. Archer SY, Meng S, Shei A & Hodin RA 1998 p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. PNAS 95 6791-6796.
2. Braun H, Koop R, Ertmer A, Nacht S & Suske G 2001 Transcription factor Sp3 is regulated by acetylation. Nucleic Acids Research 29 4994-5000.
3. Brouillet JP, Dujardin MA, Chalbos D, Rey JM, Grenier J, Lamy PJ, Maudelonde T & Pujol P 2001 Analysis of the potential contribution of oestrogen receptor (ER) beta in ER cytosolic assay of breast cancer. International Journal of Cancer 20 205-208.
4. (WAF1/CIP1) in oestrogen receptor-negative breast cancer cells. Journal of the National Cancer Institute 92 1403-1413.
5. Davis T, Kennedy C, Chiew YE, Clarke CL & deFazio A 2000 Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clinical Cancer Research 6 4334-4342.
6. Doetzlhofer A, Rotheneder H, Lagger G, Koranda M, Kurtev V, Brosch G, Wintersberger E & Seiser C 1999 Histone deacetylase 1 can repress transcription by binding to Sp1. Molecular and Cellular Biology 19 5504-5511.
7. Filipits M, Malayeri R, Suchomel RW, Pohl G, Stranzl T, Dekan G, Kaider A, Stiglbauer W, Depisch D & Pirker R 1999 Expression of the multidrug resistance protein (MRP1) in breast cancer. Anticancer Research 19 5043-5049.
8. Guenther MG, Barak O & Lazar MA 2001 The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Molecular and Cellular Biology 21 6091-6101.
9. Jenuwein T & Allis CD 2001 Translating the histone code. Science 293 1074-1080.
10. Jordan VC 1998 Molecular biology of the oestrogen receptor aids in the understanding of tamoxifen resistance and breast cancer prevention with raloxifene. Recent Results in Cancer Research 152 265-276.
11. Julia AM, Roche H, Berlion M, Lucas C, Milano G, Robert J, Bizzari JP & Canal P 1994 Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil. British Journal of Cancer 69 868-874.
12. Kim YB, Lee KH, Sugita K, Yoshida M & Hoinouchi S 1999 Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18 2461-2470.
13. (WAF1/Cip1) gene by the p53 tumor suppressor protein. Journal of Biological Chemistry 276 29116-29125.
14. Kramer OH, Gottlicher M & Heinzel T 2001 Histone deacetylase as a therapeutic target. Trends in Endocrinology and Metabolism 12 294-300.
15. Lagger G, Doetzlhofer A, Schuettengruber B, Haidweger E, Simboeck E, Tischler J, Chiocca S, Suske G, Rotheneder H, Wintersberger E & Seiser C 2003 The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Molecular and Cellular Biology 23 2669-2679.
16. Lazennec G, Bresson D, Lucas A, Chauveau C & Vignon F 2001 ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 142 4120-4130.
17. Lu S, Jenster G & Epner DE 2000 Androgen induction of cyclin-dependent kinase inhibitor p21 gene: role ofandrogen receptor and transcription factor Sp1 complex. Molecular Endocrinology 14 753-760.
18. Marks PA, Richon VM & Rifkind RA 2000 Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. Journal of the National Cancer Institute 92 1210-1216.
19. Pandolfi PP 2001 Transcription therapy for cancer. Oncogene 20 3116-3127.
20. Philips A, Chalbos D & Rochefort H 1993 Estradiol increases and anti-oestrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. Journal of Biological Chemistry 268 14103-14108.
21. Porter W, Saville B, Hoivik D & Safe S 1997 Functional synergy between the transcription factor Sp1 and the oestrogen receptor. Molecular Endocrinology 11 1569-1580.
22. Redeuilh G, Attia A, Mester J & Sabbah M 2002 Transcriptional activation by the oestrogen receptor alpha is modulated through inhibition of cyclin-dependent kinases. Oncogene 21 5773-5782.
23. Richon VM, Sandhoff TW, Rifkind RA & Marks PA 2000 Histone deacetylase inhibitor selectively induces p21 WAF1 expression and gene-associated histone acetylation. PNAS 97 10014-10019.
24. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P & Rochefort H 2001 Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Research 61 2537-2541.
25. Rundlett SE, Carmen AA, Kobayashi R, Bavykin S, Turner BM & Grunstein M 1996 HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription. PNAS 93 14503-14508.
26. Ryu H, Lee J, Olofsson BA, Mwidau A, Deodoglu A, Escudero M, Flemington E, Azizkhan-Clifford J, Ferrante RJ & Ratan RR 2003 Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. PNAS 100 4281-4286.
27. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T & Nakanishi O 1999 A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. PNAS 96 4592-4597.
28. Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV & Bates SE 2000 P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. British Journal of Cancer 83 817-825.
29. Santen RJ, Manni A, Harvey H & Redmond C 1990 Endocrine treatment of breast cancer in women. Endocrine Reviews 11 221-265.
30. Saunders N, Dicker A, Popa C, Jones S & Dahler A 1999 Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Research 59 399-404.
31. Shack S, Miller A, Liu L, Prasanna P, Thibault A & Samid D 1996 Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate. Chinical Cancer Research 2 865-872.
32. Sommer S & Fuqua SA 2001 Oestrogen receptor and breast cancer. Seminars in Cancer Biology 11 339-352.
33. Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, Nomura H & Sakai T 1997 Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochemical and Biophysical Research Communications 241 142-150.
34. Strahl BD & Allis CD 2000 The language of covalent histone modifications. Nature 403 41-45.
35. Thenot S, Charpin M, Bonnet S & Cavaillès V 1999 Oestrogen receptor cofactors expression in breast and endometrial human cancer cells. Molecular and Cellular Endocrinology 156 85-93.
36. Van Lint C, Emiliani S, Ott M & Verdin E 1996 Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO Journal 15 1112-1120.
37. Vaziri C, Stice L & Faller DV 1998 Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. Cell Growth and Differentiation 9 465-474.
38. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I & Coombes RC 2001 Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clinical Cancer Research 7 971-976.
39. Wang C, Fu M, Angeletti RH, Siconolfi-Baez L, Reutens AT, Albanese C, Lisanti MP, Katzenellenbogen BS, Kato S, Hopp T, Fuqua SA, Lopez GN, Kushner PJ & Pestell RG 2001 Direct acetylation of the oestrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. Journal of Biological Chemistry 276 18375-18383.
40. Warrell RPJ, He LZ, Richon V, Calleja E & Pandolfi PP 1998 Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. Journal of the National Cancer Institute 90 1621-1625.
41. Woodcock CL & Dimitrov S 2001 Higher-order structure of chromatin and chromosomes. Current Opinion in Genetics Development 11 130-135.
42. Xiao H, Hasegawa T & Isobe K 2000 p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor. Journal of Biological Chemistry 275 1371-1376.
43. Yoshida M, Kijima M, Akita M & Beppu T 1990 Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. Journal of Biological Chemistry 265 17174-17179.
44. Zambetti GP, Bargonetti J, Walker K, Prives C & Levine AJ 1992 Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes and Development 6 1143-1152.